Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.…
Janux Therapeutics Stock In Focus As Loss Narrows And Phase 1 Data Nears
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics (NASDAQ: JANX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 114 employees.
The shares were at 10.08 USD on 20 November 2026, down 61.9% over 52 weeks. Its 52-week range is 10.05 USD to 35.34 USD, and it trades at the bottom of that range.
Its market capitalisation is 616.73M USD.
Janux Therapeutics reports return on equity of -11.9% and revenue down 7.1% year over year.
It holds more cash than debt, a net cash position of 925.34M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 33.14 USD is 228.8% above the current price. The next earnings report is expected on 25 February 2027.